United Therapeutics Corp
NASDAQ:UTHR

Watchlist Manager
United Therapeutics Corp Logo
United Therapeutics Corp
NASDAQ:UTHR
Watchlist
Price: 363.65 USD 1.13% Market Closed
Market Cap: 16.2B USD
Have any thoughts about
United Therapeutics Corp?
Write Note
UTHR
/
Balance Sheet
/
Accumulated Depreciation

United Therapeutics Corp
Accumulated Depreciation

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

United Therapeutics Corp
Accumulated Depreciation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accumulated Depreciation CAGR 3Y CAGR 5Y CAGR 10Y
United Therapeutics Corp
NASDAQ:UTHR
Accumulated Depreciation
-$475.6m
CAGR 3-Years
-12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Accumulated Depreciation
-$7.1B
CAGR 3-Years
-8%
CAGR 5-Years
-5%
CAGR 10-Years
-4%
Gilead Sciences Inc
NASDAQ:GILD
Accumulated Depreciation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Accumulated Depreciation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Accumulated Depreciation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Accumulated Depreciation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

United Therapeutics Corp
Glance View

Market Cap
16.2B USD
Industry
Biotechnology
Economic Moat
Narrow

In the landscape of biotechnology, United Therapeutics Corp. has crafted a compelling narrative centered around innovation and transformation, principally targeting life-threatening conditions. Founded in 1996 by Martine Rothblatt, the company's inception was motivated by the urgent need to find solutions for her daughter's rare disease, pulmonary arterial hypertension (PAH). Over the years, United Therapeutics has stayed true to its pioneering ethos, focusing on creating and commercializing unique therapies that address the needs of patients with severe and often unmet health challenges. The core of its operations revolves around developing drugs that enhance survival and quality of life for individuals afflicted by PAH and other similar illnesses. Such dedication to research and pharmaceutical development has fostered a robust product pipeline, including therapeutics like Remodulin and Tyvaso, which play pivotal roles in the company's revenue generation. Financially, United Therapeutics sustains its momentum through a blend of strong patent portfolios and strategic market positioning, ensuring both competitive advantage and an ongoing revenue stream. By maintaining a keen focus on specific niches within the biotechnology sector, the company minimizes competition while maximizing the impact of its therapeutic solutions. Its business model thrives on the supply of specialized medications, which, given their critical nature, command premium pricing. Yet, United Therapeutics doesn’t solely pivot around drug sales; it is deeply invested in the future of medicine, notably venturing into areas like organ manufacturing and xenotransplantation, where it seeks to address broader and more complex health challenges. Through a blend of innovation, strategic partnerships, and diversification into emerging medical fields, United Therapeutics continues to cement its reputation as a leader in biotechnological advancement.

UTHR Intrinsic Value
375 USD
Undervaluation 3%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is United Therapeutics Corp's Accumulated Depreciation?
Accumulated Depreciation
-475.6m USD

Based on the financial report for Sep 30, 2024, United Therapeutics Corp's Accumulated Depreciation amounts to -475.6m USD.

What is United Therapeutics Corp's Accumulated Depreciation growth rate?
Accumulated Depreciation CAGR 3Y
-12%

Over the last year, the Accumulated Depreciation growth was -13%. The average annual Accumulated Depreciation growth rates for United Therapeutics Corp have been -12% over the past three years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.